WaveMan
WaveMan · Company
ALMS · Alumis Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ALMS Alumis (ALMS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001847367
Quote by TradingView
Activist 13D
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
105
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $203.9K priced

What the filings say about ALMS

Insiders, 180 days
+$6.7M net bought
1 buyer · 7 sellers · 0% of sales under a 10b5-1 plan
Activist stakes (13D), 180 days
1 filing
Largest: 14.5% of the class

Alumis insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ALUMIS INC. insiders bought a net $6.7M of stock across 67 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
AKKARAJU SRINIVAS
Director
SELL
2026-09-09 SECtraded 2026-09-08
48,066
$507.0K
-32.9%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on Sep 4, 2026.
  • +279.2% median (+217.7% mean) 90-day return after 16 previous buys.
  • The trade is 1.0% of the 4,663,735 shares held after it.
  • No other insider sold within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AKKARAJU SRINIVAS sold about $507.0K of ALMS on Sep 8, 2026, the largest insider sale at the company on our record; 105 funds added in the latest 13F quarter.
AKKARAJU SRINIVAS
Director
SELL
2026-09-09 SECtraded 2026-09-08
48,065
$507.0K
-32.9%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on Sep 4, 2026.
  • +279.2% median (+217.7% mean) 90-day return after 16 previous buys.
  • The trade is 2.4% of the 2,025,493 shares held after it.
  • No other insider sold within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AKKARAJU SRINIVAS sold about $507.0K of ALMS on Sep 8, 2026, the largest insider sale at the company on our record; 105 funds added in the latest 13F quarter.
AKKARAJU SRINIVAS
Director
BUY
2026-09-09 SECtraded 2026-09-08
273,291
$2.9M
-32.9%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on Sep 4, 2026.
  • +279.2% median (+217.7% mean) 90-day return after 16 previous buys.
  • The trade is 5.5% of the 4,937,026 shares held after it.
  • No other insider bought within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AKKARAJU SRINIVAS bought about $2.9M of ALMS on Sep 8, 2026; 105 funds added in the latest 13F quarter.
AKKARAJU SRINIVAS
Director
BUY
2026-09-09 SECtraded 2026-09-08
273,290
$2.9M
-32.9%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 buys), the last on Sep 4, 2026.
  • +279.2% median (+217.7% mean) 90-day return after 16 previous buys.
  • The trade is 11.9% of the 2,298,783 shares held after it.
  • No other insider bought within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AKKARAJU SRINIVAS bought about $2.9M of ALMS on Sep 8, 2026; 105 funds added in the latest 13F quarter.
AKKARAJU SRINIVAS
Director
BUY
2026-09-09 SECtraded 2026-09-04
220,070
$2.5M
-32.9%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (19 buys), the last on Jan 9, 2026.
  • +279.2% median (+217.7% mean) 90-day return after 16 previous buys.
  • The trade is 4.7% of the 4,711,801 shares held after it.
  • No other insider bought within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director AKKARAJU SRINIVAS bought about $2.5M of ALMS on Sep 4, 2026; 105 funds added in the latest 13F quarter.
67 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 62 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$6.7M over 180 days
+$6.9M over 90 days
more than 95% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
105 funds bought in last quarter
more than 71% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-1011.7% net margin
below 86% of Pharma & Biotech
Buybacks
$17.0K repurchased, FY to 2025-12-31
below 99% of Pharma & Biotech
Short interest
11.3% of the float short (float per yahoo 2026-10-26) · 3.6 days to cover · settled 2026-09-30
The situation: each line is one rule over one dataset
Foresite Capital Fund VI LP disclosed a 5%+ stake (3.5%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ALMS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+44.0%12M
-2%+184%+371%+557%2025-102025-122026-022026-042026-062026-082026-10 2026-01-09 · AKKARAJU SRINIVAS bought $10.0M2026-01-08 · Foresite Labs, LLC bought $5.0M2026-01-08 · Foresite Labs Fund I, L.P. bought $5.0M2026-01-08 · Tananbaum James B. bought $5.0M2026-09-08 · AKKARAJU SRINIVAS bought $2.9M2026-09-08 · AKKARAJU SRINIVAS bought $2.9M2026-09-04 · AKKARAJU SRINIVAS bought $2.5M2026-01-08 · Foresite Labs, LLC bought $2.0M2026-01-08 · Foresite Labs Fund I, L.P. bought $2.0M2026-01-08 · Tananbaum James B. bought $2.0M2025-11-13 · AKKARAJU SRINIVAS bought $1.4M2025-11-19 · Foresite Labs Affiliates 2021, LLC bought $1.2M2025-11-19 · Foresite Capital Management VI LLC bought $1.2M2025-11-19 · Tananbaum James B. bought $1.2M2025-11-20 · AKKARAJU SRINIVAS bought $905.3K2025-11-19 · AKKARAJU SRINIVAS bought $903.8K2025-11-17 · Foresite Labs Affiliates 2021, LLC bought $838.5K2025-11-17 · Foresite Capital Management VI LLC bought $838.5K2025-11-17 · Tananbaum James B. bought $838.5K2025-12-03 · AKKARAJU SRINIVAS bought $775.0K2025-11-18 · Foresite Labs Affiliates 2021, LLC bought $726.5K2025-11-18 · Foresite Capital Management VI LLC bought $726.5K2025-11-18 · Tananbaum James B. bought $726.5K2025-12-02 · AKKARAJU SRINIVAS bought $724.8K2025-12-05 · AKKARAJU SRINIVAS bought $701.0K2025-12-01 · AKKARAJU SRINIVAS bought $644.2K2025-11-18 · AKKARAJU SRINIVAS bought $621.0K2025-12-05 · AKKARAJU SRINIVAS bought $581.5K2025-12-05 · AKKARAJU SRINIVAS bought $551.3K2025-12-04 · AKKARAJU SRINIVAS bought $540.1K2025-11-21 · Foresite Labs Fund I, L.P. bought $532.9K2025-11-21 · Tananbaum James B. bought $532.9K2025-11-21 · Foresite Labs Affiliates 2021, LLC bought $532.9K2026-09-08 · AKKARAJU SRINIVAS sold $507.0K2026-09-08 · AKKARAJU SRINIVAS sold $507.0K2025-11-26 · AKKARAJU SRINIVAS bought $370.8K2025-11-28 · AKKARAJU SRINIVAS bought $295.7K2025-11-17 · Foresite Labs Affiliates 2021, LLC bought $280.0K2025-11-17 · Foresite Capital Management VI LLC bought $280.0K2025-11-17 · Tananbaum James B. bought $280.0K2026-07-06 · Pangali Sanam sold $140.0K2026-08-03 · Schroer John R. sold $86.5K2026-08-17 · Foresite Capital Fund VI LP filed a 5%+ stake (3.5%)2026-08-17 · Foresite Capital Management VI, LLC filed a 5%+ stake (3.5%)2026-08-17 · Foresite Capital Fund V, L.P. filed a 5%+ stake (5.6%)2026-08-17 · Foresite Capital Management V, LLC filed a 5%+ stake (5.6%)2026-08-17 · Foresite Capital Opportunity Fund V, L.P. filed a 5%+ stake (5.4%)2026-08-17 · Foresite Capital Opportunity Management V, LLC filed a 5%+ stake (5.4%)2026-08-17 · James B. Tananbaum filed a 5%+ stake (14.5%)2026-07-06 · SANAMPREET PANGALI filed to sell $140.0K
Insider buyInsider sell13D/G stakeForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ALMS: institutional holders (13F)

13F holdings, latest reported quarter
AyurMaya Capital Management Company, LP
15,139,707 sh
$426.0M
BlackRock, Inc.
8,218,151 sh
$231.3M
FMR LLC
6,769,170 sh
$190.5M
Deep Track Capital, LP
6,348,558 sh
$178.6M
SAMSARA BIOCAPITAL, LLC
6,345,219 sh
$178.6M

Congress trades in ALMS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Foresite Capital Fund VI LP
Activist 13D · 2026-08-17
3.5%
Foresite Capital Management VI, LLC
Activist 13D · 2026-08-17
3.5%
Foresite Capital Fund V, L.P.
Activist 13D · 2026-08-17
5.6%
Foresite Capital Management V, LLC
Activist 13D · 2026-08-17
5.6%
Foresite Capital Opportunity Fund V, L.P.
Activist 13D · 2026-08-17
5.4%

ALMS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
SANAMPREET PANGALI
Filed 2026-07-06
$140.0K

ALMS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$9.2M position · as of 2026-06-30
2.1%
PROFUND VP PHARMACEUTICALS
$239.1K position · as of 2026-06-30
2.1%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$330.8K position · as of 2026-07-31
1.6%
Fidelity Advisor Biotechnology Fund
$26.7M position · as of 2026-07-31
1.2%
Virtus Biotech Clinical Trials Etf
$363.6K position · as of 2026-07-31
0.8%
Royce Smaller-Companies Growth Fund
$1.7M position · as of 2026-06-30
0.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
13 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
6
Phase 1
0 active
4
Phase 2
2 active
3
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows a net $6.7M bought by insiders over 180 days, 105 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ALMS financials

Net margin
-1011.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$7.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-5,933%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$351.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-93.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-74.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-90.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no share count filed
FCF yield
n/a
no share count filed
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$24.1Mn/an/a
Operating income-$453.8M-$300.8M-$158.2M
Net income-$243.3M-$294.2M-$155.0M
EPS (diluted)-2.86-10.38-72.08
Operating cash flow-$369.5M-$255.1M-$130.0M
Cash$89.7M$169.5M$46.0M
Buybacks$17.0K$6.0K$64.0K
SEC XBRL, fiscal years, as known on 2026-10-28

ALMS Stock Sonar score 4/7 axes

Find similar shapesCompare

ALMS ranks highest on insider conviction (76th percentile) and institutional and government (71st), and lowest on profitability (32nd), among Pharma & Biotech peers.

Profitability
32
Inputs
  • Return on equity-93.6% · 35 pct, sector of 545
  • Return on assets-74.9% · 32 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-90.9% · 29 pct, sector of 576
Insider conviction
76
Inputs
  • Net Form 4 buying (codes P and S), 180d$6.7M · 95 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
71
Inputs
  • Funds adding, latest quarter105 · 71 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
37
Inputs
  • Short interest, % of float+11.3% · 36 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+13.0% · 38 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ALMS filings, in plain words

Are Alumis insiders buying or selling ALMS?

In the 180 days to 2026-10-28, Alumis insiders were net buyers, a net $6.7M: $8.3M of purchases and $1.5M of sales reported on Form 4, by 1 buyer and 7 sellers.

Read the full summary

In the 180 days to 2026-10-28, Alumis insiders were net buyers of ALMS, a net $6.7M across purchases and sales reported on Form 4 by 1 buyer and 7 sellers. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. 1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 14.5% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies